- Home
- PODD vs BIRK Comparison
PODD vs BIRK Comparison
Compare PODD & BIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PODD | BIRK |
|---|---|---|
| Founded | 2000 | 1774 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.5B |
| IPO Year | 2007 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PODD | BIRK |
|---|---|---|
| Price | $163.72 | $42.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 14 |
| Target Price | ★ $341.48 | $61.43 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $2,708,100,000.00 | N/A |
| Revenue This Year | $24.55 | $13.71 |
| Revenue Next Year | $19.18 | $14.30 |
| P/E Ratio | $128.75 | ★ $17.48 |
| Revenue Growth | ★ 30.73 | N/A |
| 52 Week Low | $138.79 | $31.33 |
| 52 Week High | $354.88 | $53.53 |
Technical Indicators
Market Signals| Indicator | PODD | BIRK |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 43.68 |
| Support Level | $141.67 | $40.98 |
| Resistance Level | $164.59 | $45.79 |
| Average True Range (ATR) | 6.04 | 1.87 |
| MACD | 0.83 | -0.41 |
| Stochastic Oscillator | 62.33 | 15.19 |
Price Performance
Historical ComparisonAbout PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
About BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.